-
Cureus Oct 2023Heparin, a mixture of sulfated polymorphic polysaccharides (glycosaminoglycan) chains of variable lengths and weights and a natural anticoagulant, is widely used in... (Review)
Review
Heparin, a mixture of sulfated polymorphic polysaccharides (glycosaminoglycan) chains of variable lengths and weights and a natural anticoagulant, is widely used in medical practice to prevent intravascular blood coagulation. Heparin has demonstrated antithrombotic and anti-inflammatory activity, and it is mostly administered systemically (intravenously or subcutaneously) for primary or secondary prevention of venous thromboembolism after surgical interventions, or immobilized patients, or on short-term antithrombotic therapy of patients with atrial fibrillation who must undergo treatment. However, since systemic administration of heparin could be, in certain cases, linked to an increased risk of bleeding, topical heparin is widely used for the prevention and treatment of local symptoms of peripheral vascular disorders, such as venous insufficiency, varicose veins, or superficial thrombophlebitis. This review summarizes the main safety and efficacy characteristics of the topical formulation of Heparin in Gel form (1000 International Units of Heparin/g Gel) currently in use, which has demonstrated an excellent efficacy and tolerability profile in reducing signs and symptoms of peripheral vascular disease, e.g., varicose syndromes and their complications, phlebothrombosis, thrombophlebitis, superficial periphlebitis, varicose ulcers, for post-operative varicophlebitis, sequelae of saphenectomy, for traumas and contusions, local edemas and infiltrates, subcutaneous hematoma and for traumatic affections of musculotendinous and capsuloligamentous apparatuses.
PubMed: 38022089
DOI: 10.7759/cureus.47418 -
British Journal of Haematology Mar 2015Superficial vein thrombosis (SVT) was considered to be a benign and self-limiting condition. However, it is now appreciated that a significant proportion of those... (Review)
Review
Superficial vein thrombosis (SVT) was considered to be a benign and self-limiting condition. However, it is now appreciated that a significant proportion of those presenting with SVT will have concomitant deep vein thrombosis or pulmonary embolism, or are at significant risk of developing deep venous thromboembolism. Potential therapeutic options include topical preparations, compression therapy (stockings, bandages), medication such as non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulants (therapeutic or prophylactic doses) and surgery, ligation or stripping, of superficial veins. The treatment of choice is therapeutic/intermediate dose low molecular weight heparin or prophylactic dose fondaparinux administered for 4-6 weeks. The cost-effectiveness of treatment is a concern and more targeted therapy is required.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Risk Factors; Time Factors; Venous Thrombosis
PubMed: 25521017
DOI: 10.1111/bjh.13255 -
Cureus May 2020Klippel-Trenaunay Syndrome (KTS) is a rare and sporadic congenital disorder, characterized by the classical triad of port-wine stains, varicosities along with bone and... (Review)
Review
Klippel-Trenaunay Syndrome (KTS) is a rare and sporadic congenital disorder, characterized by the classical triad of port-wine stains, varicosities along with bone and soft tissue hypertrophy. Symptoms of Klippel-Trenaunay Syndrome include pain, swelling, lymphedema, bleeding, superficial thrombophlebitis, and deep vein thrombosis. The etiology remains indistinct and has been attributed to both genetic and environmental factors. In most cases, a thorough history and clinical examination is enough for the diagnosis of Klippel Trenaunay Syndrome. However, when certain complications are present, noninvasive imaging techniques are used for the diagnosis and evaluation of the disease in patients. Due to the diversity of presentation, a multidisciplinary approach is essential for the proper management of such patients. At present, there is no cure for the disease; rather, symptomatic treatment is employed in order to improve the patients' quality of life. In this review, we provide a brief overview of the clinicopathological profile and management of Klippel-Trenaunay Syndrome.
PubMed: 32528762
DOI: 10.7759/cureus.8023 -
The American Journal of Case Reports Jan 2020BACKGROUND Multifocal superficial thrombophlebitis is a rare clinical manifestation with wide differential diagnosis in relation to the background disease. CASE REPORT...
BACKGROUND Multifocal superficial thrombophlebitis is a rare clinical manifestation with wide differential diagnosis in relation to the background disease. CASE REPORT Here we report on 2 patients who presented with a systemic inflammatory response, multifocal thrombophlebitis, and orbital inflammation in whom a diagnosis of a defined background disease could not be established. CONCLUSIONS The clinical pattern of our 2 cases might represent a distinctive, not yet defined systemic medical condition.
Topics: Aged; Humans; Inflammation; Male; Orbital Cellulitis; Thrombophlebitis; Undiagnosed Diseases
PubMed: 31932573
DOI: 10.12659/AJCR.919715 -
The Israel Medical Association Journal... Dec 2022Data regarding risk factors for superficial thrombophlebitis (STP) cases presenting to a hospital is limited.
BACKGROUND
Data regarding risk factors for superficial thrombophlebitis (STP) cases presenting to a hospital is limited.
OBJECTIVES
To investigate and stratify clinical and laboratory risk factors for STP.
METHODS
We conducted a retrospective case control study comparing patients presenting to the emergency department with STP and age- and gender-matched controls. We collected data on multiple risk factors and five blood indices.
RESULTS
The study comprised 151 patients and matched controls. Patients with STP were more likely to have varicose veins (43.7% vs. 5.3%, P < 0.001), recent immobilization (14.6% vs. 1.3%, P < 0.001), obesity (36.4% vs. 18.5%, P = 0.001), a history of venous thromboembolism (VTE) or STP (27.2% vs. 0.7%, P < 0.001), and inherited thrombophilia (9.3% vs. 1.3%, P = 0.002). Following multivariate analysis, all five risk factors remained significant, with a history of VTE or STP associated with the largest risk (odds ratio [OR] 35.7), followed by immobilization (OR 22.3), varicose veins (OR 12.1), inherited thrombophilia (OR 6.1), and obesity (OR 2.7). Mean platelet volume was higher (8.5 vs 7.9 fl, P = 0.003) in STP cases.
CONCLUSIONS
A history of VTE or STP, immobilization, varicose veins, inherited thrombophilia, and obesity serve as independent clinical risk factors for STP presenting to hospital.
Topics: Humans; Retrospective Studies; Case-Control Studies; Venous Thromboembolism; Thrombophlebitis; Risk Factors; Varicose Veins; Obesity; Thrombophilia
PubMed: 36573782
DOI: No ID Found -
Journal of Anaesthesiology, Clinical... 2021
PubMed: 34349392
DOI: 10.4103/joacp.JOACP_331_18 -
Diagnostic and Interventional Imaging Feb 2012Benign mastitis is a rare disease and its management is difficult. The diagnostic challenge is to distinguish it from carcinomatous mastitis. We make a distinction...
Benign mastitis is a rare disease and its management is difficult. The diagnostic challenge is to distinguish it from carcinomatous mastitis. We make a distinction between acute mastitis secondary to an infection, to inflammation around a benign structure or to superficial thrombophlebitis, and chronic, principally plasma cell and idiopathic granulomatous mastitis. Imaging is often non-specific but we need to know and look for certain ultrasound, mammogram or magnetic resonance imaging (MRI) signs to give a pointer as early as possible towards a benign aetiology. A biopsy should be undertaken systematically where there is the slightest diagnostic doubt, to avoid failing to recognise a carcinomatous mastitis.
Topics: Acute Disease; Female; Humans; Magnetic Resonance Imaging; Mammography; Mastitis; Syndrome; Ultrasonography
PubMed: 22305592
DOI: 10.1016/j.diii.2011.12.002 -
Anesthesia, Essays and Researches 2019The association of superficial thrombophlebitis (ST) with deep-venous thrombosis varies between 6% and 44%. Thus, prevention of ST is important. The aim of this study...
Comparison of Heparin Quick Penetrating Solution and Diclofenac Quick Penetrating Solution for the Prevention of Superficial Thrombophlebitis Caused by Peripheral Venous Cannulation: A Randomized Double-Blind Study.
BACKGROUND AND AIMS
The association of superficial thrombophlebitis (ST) with deep-venous thrombosis varies between 6% and 44%. Thus, prevention of ST is important. The aim of this study was to compare the efficacy of topical quick penetrating solution (QPS) of heparin 1000 IU/mL versus diclofenac QPS for prevention of postinfusion ST.
SETTINGS AND DESIGN
This is a randomized, controlled, double-blind study.
MATERIALS AND METHODS
The study was done after ethical clearance and Clinical Trial Registry- India registration to compare 100 patients for the prevention of ST with application of heparin QPS and diclofenac QPS at regular intervals. Patients were randomized into two groups (Group H [control group] - heparin QPS group and Group D - diclofenac QPS group) and the assigned treatment was applied four times daily. The appearance of thrombophlebitis was graded on the basis of infusion nursing society scale. The site of venous cannulation was inspected every 6 h for any changes for the next 5 days.
STATISTICAL ANALYSIS
The parametric data were analyzed using Student's -test and nonparametric data were analyzed by Kruskal-Wallis test.
RESULTS
Of 98, only 10 patients developed thrombophlebitis and all belonged to Group D (23%). No patient belonging to Group H developed thrombophlebitis (0%). This difference was statistically significant ( = 0.034).
CONCLUSION
The QPS formulation of heparine and diclofenac was effective in preventing thrombophlebitis. Heparine QPS is more effective than diclofenac QPS for the same.
PubMed: 31031497
DOI: 10.4103/aer.AER_189_18 -
Internal Medicine Journal Nov 2022Cannula provoked upper extremity superficial vein thrombophlebitis (UESVT) is common. Retrospective audit of 93 consecutive patients, 51% male, median age 57 years...
Cannula provoked upper extremity superficial vein thrombophlebitis (UESVT) is common. Retrospective audit of 93 consecutive patients, 51% male, median age 57 years (range 20-91), with symptomatic UESVT revealed varied management including symptomatic management (37%), prophylactic (37%) and higher dose anticoagulation (27%). There was 2% (95% confidence interval (CI) 0-7.6) thrombus extension and 1% (95% CI 0-5.9) major bleeding, both limited to cancer. We argue anticoagulation is unnecessary in most UESVT patients.
Topics: Male; Humans; Young Adult; Adult; Middle Aged; Aged; Aged, 80 and over; Female; Cannula; Retrospective Studies; Upper Extremity; Thrombophlebitis; Anticoagulants
PubMed: 36326238
DOI: 10.1111/imj.15951